Author:
Of Zhejiang Medical Association Society of Obstetrics and Gynecology,Of Zhejiang Medical Association Society of Urology,Of Zhejiang Anticancer Association Committee of Breast Cancer,of Zhejiang Anticancer Association (preparation) Committee of Clinical Pharmacy on Oncology,Of Zhejiang Society for Mathematical Medicine Committee of Urology
Publisher
China Science Publishing & Media Ltd.
Reference50 articles.
1. FRIEDLANDER M, BANERJEE S, MILESHKIN L. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum‐sensitive recurrent ovarian cancer[J]. Asia Pac J Clin Oncol, 2016, 12: 323-331.
2. O’CEARBHAILL R E. Using PARP inhibitors in advanced ovarian cancer[J]. Oncology ( Williston Park), 2018, 32(7): 339-343.
3. TEW W P, LACCHETTI C, ELLIS A. PARP inhibitors in the management of ovarian cancer: ASCO guideline[J]. J Clin Oncol, 2020, 38: 3468-3493.
4. 中国抗癌协会妇科肿瘤专业委员会. PARP抑制剂不良反应管理的中国专家共识(2021年版)[J]. 中国实用妇科与产科杂志, 2021, 37(11): 1119-1130.
5. BAI P. Biology of poly (ADP-ribose) polymerases: the factotums of cell maintenance[J]. Mol Cell, 2015, 58: 947-958.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献